New Drugs Under Development for Cardiovascular Prevention

Early Vascular Aging (EVA): New Directions in Cardiovascular Protection

Volumn , Issue , 2015, Pages 323-334

  Laurent, Stéphane ^a,b,c   Steckelings, Ulrike M ^d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cardiovascular prevention; Drug effects; Hypertension; Pharmacology; Therapy

Indexed keywords

EID: 84997783817     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-801387-8.000302     Document Type: Chapter

References (92)

1. Laurent S., Schlaich M., Esler M. New drugs, procedure and devices for hypertension. Lancet 2012, 380:591-600.
2. Nilsson P., Boutouyrie P., Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009, 54:3-10.
3. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003, 21:3-12.
4. Monnier V.M., Sell D.R., Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 2005, 1043:567-581.
5. Bruel A., Oxlund H. Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Atherosclerosis 1996, 127:155-165.
6. Herrmann K.L., McCulloch A.D., Omens J.H. Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 2003, 284:H1277-H1284.
7. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., Huijberts M.S., Poitevin P., Swennen G.N., et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 95:4630-4634.
8. Bolton W.K., Cattran D.C., Williams M.E., Adler S.G., Appel G.B., Cartwright K., et al. ACTION I Investigator Group Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24:32-40.
9. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A., deGroof R.C., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
10. Zieman S.J., Melenovsky V., Clattenburg L., Corretti M.C., Capriotti A., Gerstenblith G., et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007, 25:577-583.
11. London G.M., Marchais S.J., Guérin A.P., Boutouyrie P., Métivier F., de Vernejoul M.C. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008, 19:1827-1835.
12. Rennenberg R.J., Schurgers L.J., Kroon A.A., Stehouwer C.D. Arterial calcifications. J Cell Mol Med 2010, 14:2203-2210.
13. Lanzer P., Boehm M., Sorribas V., Thiriet M., Janzen J., Zeller T., et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J 2014, 23:1515-1525.
14. Duchier J., Iannascoli F., Safar M. Antihypertensive effect of sustained release isosorbide dinitrate for isolated systolic hypertension in the elderly. Am J Cardiol 1987, 60:99-108.
15. Starmans-Kool M.J.F., Kleinjans H.A.J., Lustermans F.A.T., Kragten J.A., Breed J.S., Van Bortel L.M.A.B. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens 1998, 12:557-561.
16. Laurent S., Arcaro G., Benetos A., Lafleche A., Hoeks A., Safar M. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. J Cardiovasc Pharmacol 1992, 19:641-649.
17. Oliver J.J., Dear J.W., Webb D.J. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010, 56:62-67.
18. Oliver J.J., Melville V.P., Webb D.J. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006, 48:622-627.
19. Broderick K.E., Alvarez L., Balasubramanian M., Belke D.D., Makino A., Chan A., et al. Nitrosyl-cobinamide, a new and direct nitric oxide releasing drug effective in vivo. Exp Biol Med (Maywood) 2007, 232:1432-1440.
20. Breschi M.C., Calderone V., Digiacomo M., Macchia M., Martelli A., Martinotti E., et al. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties. J Med Chem 2006, 49:2628-2639.
21. Li Y.Q., Ji H., Zhang Y.H., Shi W.B., Meng Z.K., Chen X.Y., et al. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur J Pharmacol 2007, 577:100-108.
22. Weber M.A. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009, 122:S16-S22.
23. Corti R., Burnett J.C., Rouleau J.L., Ruschitzka F., Lüscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?. Circulation 2001, 104:1856-1862.
24. Dive V., Chang C.F., Yiotakis A., Sturrock E.D. Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality?. Curr Pharm Des 2009, 15:3606-3621.
25. Daull P., Jeng A.Y., Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007, 50:247-256.
26. Mitchell G.F., Izzo J.L., Lacourcière Y., Ouellet J.P., Neutel J., Qian C., et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002, 105:2955-2961.
27. Kosoglou T., Herron J.M., Chen R., Given B., Sybertz E.J., Affrime M.B. Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation 1990, 82:2201-2210.
28. Laurent S., Boutouyrie P., Azizi M., Marie C., Gros C., Schwartz J.C., et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and ACE, in rats and humans. Hypertension 2000, 35:1148-1153.
29. Weber M.A. Vasopeptidase inhibitors. Lancet 2001, 358:1525-1532.
30. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103-111.
31. Campbell D.J. Vasopeptidase inhibition: a double-edged sword?. Hypertension 2003, 41:383-389.
32. Adam A., Cugno M., Molinaro G., Perez M., Lepage Y., Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002, 359:2088-2089.
33. Fryer R.M., Segreti J., Banfor P.N., Widomski D.L., Backes B.J., Lin C.W., et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008, 153:947-955.
34. Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008, 9:301-309.
35. Azizi M., Bissery A., Peyrard S., Guyene T.T., Ozoux M.L., Floch A., et al. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clin Pharmacol Ther 2006, 79:49-61.
36. Kalk P., Sharkovska Y., Kashina E., von Websky K., Relle K., Pfab T., et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 2011, 57:755-763.
37. Jullien N., Makritis A., Georgiadis D., Beau F., Yiotakis A., Dive V. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem 2010, 53:208-220.
38. Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Saylan M., Sarangapani R., Maahs S., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010, 50:401-414.
39. Ruilope L.M., Dukat A., Bohm M., Lacourciere Y., Gong J., Lefkowitz M.P. Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375:1255-1266.
40. Grossmann C., Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53-62.
41. Amar L., Azizi M., Menard J., Peyrard S., Watson C., Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010, 56:831-838.
42. Calhoun D.A., White W.B., Krum H., Guo W., Bermann G., Trapani A., et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011, 124:1945-1955.
43. Steckelings U.M., Unger T. The renin-angiotensin-aldosterone system. Manual of hypertension of the European society of hypertension 2008, 110-116. Informa Healthcare, London. G. Mancia, G. Grassi, S.E. Kjeldsen (Eds.).
44. Iwai M., Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res Off J Jpn Soc Hypertens 2009, 32:533-536.
45. Santos R.A., Ferreira A.J., Verano-Braga T., Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013, 216:R1-R17.
46. Porrello E.R., Delbridge L.M.D., Thomas W.G. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci Landmark Ed 2009, 14:958-972.
47. Steckelings U.M., Kaschina E., Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005, 26:1401-1409.
48. Santos R.A. Angiotensin-(1-7). Hypertension 2014, 63:1138-1147.
49. Whitebread S., Mele M., Kamber B., de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989, 163:284-291.
50. Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A.K., Wu X., et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004, 47:5995-6008.
51. Steckelings U.M., Larhed M., Hallberg A., Widdop R.E., Jones E.S., Wallinder C., et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2010, doi:10.1016/j.coph.2010.11.002.
52. Danyel L.A., Schmerler P., Paulis L., Unger T., Steckelings U.M. Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integr Blood Press Control 2013, 6:153-161.
53. Paulis L., Becker S.T., Lucht K., Schwengel K., Slavic S., Kaschina E., et al. Direct AT2 receptor stimulation in L-NAME-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 2012, 59:485-492.
54. Rehman A., Leibowitz A., Yamamoto N., Rautureau Y., Paradis P., Schiffrin E.L. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012, 59:291-299.
55. Joseph J.P., Mecca A.P., Regenhardt R.W., Bennion D.M., Rodríguez V., Desland F., et al. The angiotensin type 2 receptor agonist compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014, 81:134-141.
56. McCarthy C.A., Vinh A., Miller A.A., Hallberg A., Alterman M., Callaway J.K., et al. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One 2014, 9:e95762.
57. Dhande I., Ma W., Hussain T. Angiotensin A.T.(2) receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production. Hypertens Res 2015, 38:21-29.
58. Gao J., Zhang H., Le K.D., Chao J., Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens 2011, 24:724-730.
59. Shraim N., Mertens B., Clinckers R., Sarre S., Michotte Y., Van Eeckhaut A. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J Neurosci Methods 2011, 202:137-142.
60. Bader M., Santos R.A., Unger T., Steckelings U.M. New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst 2012, 13:505-508.
61. Ferreira A.J., Bader M., Santos R.A. Therapeutic targeting of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat 2012, 22:567-574.
62. Rodgers K.E., Dizerega G.S. Contribution of the local RAS to hematopoietic function: a novel therapeutic target. Front Endocrinol 2013, 4:157-163.
63. Merrill D.C., Karoly M., Chen K., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002, 18:239-245.
64. Haschke M., Schuster M., Poglitsch M., Loibner H., Salzberg M., Bruggisser M., et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013, 52:783-792.
65. Hernández Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A.S., et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51:1312-1317.
66. Nguyen G., Delarue F., Burcklé C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
67. Rousselle A., Sihn G., Rotteveel M., Bader M. (Pro)renin receptor and V-ATPase: from Drosophila to humans. Clin Sci Lond Engl 2014, 126:529-536.
68. Ichihara A., Hayashi M., Kaneshiro Y., Suzuki F., Nakagawa T., Tada Y., et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114:1128-1135.
69. Funke-Kaiser H., Zollmann F.S., Schefe J.H., Unger T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res Off J Jpn Soc Hypertens 2010, 33:98-104.
70. Zini S., Fournie-Zaluski M.C., Chauvel E., Roques B.P., Corvol P., Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A 1996, 93:11968-11973.
71. Bodineau L., Frugière A., Marc Y., Inguimbert N., Fassot C., Balavoine F., et al. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008, 51:1318-1325.
72. Balavoine F., Azizi M., Bergerot D., De Mota N., Patouret R., Roques B.P., et al. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. Clin Pharmacokinet 2014, 53:385-395.
73. Levin E.R. Endothelins. N Engl J Med 1995, 333:356-363.
74. Clozel M., Breu V., Burri K., Cassal J.M., Fischli W., Gray G.A., et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993, 365:759-761.
75. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension investigators. N Engl J Med 1998, 338:784-790.
76. Weber M.A., Black H., Bakris G., Krum H., Linas S., Weiss R., et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423-1431.
77. Goddard J., Johnston N.R., Hand M.F., Cumming A.D., Rabelink T.J., Rankin A.J., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193.
78. Dhaun N., MacIntyre I.M., Kerr D., Melville V., Johnston N.R., Haughie S., et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011, 57:772-779.
79. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009, 32:826-834.
80. Casimiro-Garcia A., Filzen G.F., Flynn D., Bigge C.F., Chen J., Davis J.A., et al. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-β. J Med Chem 2011, 54:4219-4233.
81. Aubert G., Lansdorp P.M. Telomeres and aging. Physiol Rev 2008, 88:557-579.
82. Tarkanyi I., Aradi J. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Biochimie 2008, 90:156-172.
83. Scaffidi P., Misteli T. Lamin A-dependent nuclear defects in human aging. Science 2006, 312:1059-1063.
84. Hutchison C.J. Lamins: building blocks or regulators of gene expression?. Nat Rev Mol Cell Biol 2002, 3:848-858.
85. Verstraeten V.L., Ji J.Y., Cummings K.S., Lee R.T., Lammerding J. Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. Aging Cell 2008, 7:383-393.
86. Yang S.H., Qiao X., Fong L.G., Young S.G. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta 2008, 1781:36-39.
87. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
88. Kawano K., Ogata N., Chiano M., Molloy H., Kleyn P., Spector T.D., et al. Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 2002, 17:1744-1751.
89. Arking D.E., Becker D.M., Yanek L.R., Fallin D., Judge D.P., Moy T.F., et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003, 72:1154-1161.
90. Kim Y., Kim J.H., Nam Y.J., Kong M., Kim Y.J., Yu K.H., et al. Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett 2006, 407:189-194.
91. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280:1015-1020.
92. Saito Y., Nakamura T., Ohyama Y., Suzuki T., Iida A., Shiraki-Iida T., et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000, 276:767-772.